-
Most Recent
Healthcare Stocks
Healthcare encompasses a wide range of organized services to prevent, treat, and diagnose medical needs and mental illnesses. The $336 billion market is expected to grow at a compound annual growth rate of 8% until 2030, demonstrating the necessity of adequate healthcare. Healthcare companies, ranging from retailer CVS to insurance giant UnitedHealth, provide these services to a massive customer base.
7 Recession-Resistant Stocks to Hold Onto for Dear Life in 2024
These seven recession-resistant stocks offer stability and potential growth even in challenging economic conditions.
7 Dependable Dividend Stocks for Long-Term Income
Explore the best dividend stocks for long-term income excelling in the healthcare, retail, tobacco and home improvement markets.
3 Pharmaceutical Stocks That Can Surge Higher Even if The Markets Correct
These are the pharmaceutical stocks to buy as they represent undervalued companies with a deep clinical pipeline that will support growth.
Other industries you might be interested in
Recent Healthcare Stocks Articles
3 Health Care Stocks in Tip-Top Shape, Poised for Growth
Baby boomers are retiring. This, coupled with the beginning of cold and flu season, makes now the perfect time to start thinking about health care stocks.
Investors Still Must Pick Generic Drug Companies By Hand
The high-risk generic drug sector still is without an ETF, leaving investors to weed out the pharmaceutical winners and losers for themselves.
7 ‘Baby’ Booming Health Care Stocks to Buy Now
Health care spending is expected to skyrocket thanks to the aging baby boomers. It’s no wonder stocks like ABC are doing so well. Buy them now.
Biogen Is in the Right Place at the Right Time
BIIB's promising multiple scerlosis drug BG-12 could be a huge winner, just when Novartis' entry is stumbling.
Onyx Pharma May See Suitors Lining Up
The company's current and future drugs are likely attractive to larger companies faced with slowing growth.
Ranbaxy Closes In on FDA Approval for Generic Lipitor
Ranbaxy could sell $650 million worth of the drug in its first 180 days. But Pfizer is battling hard to keep branded Lipitor alive.
Forget Amgen — Buy This Pharmaceutical Stock Instead
Amgen is a world-class biotech company, but its big growth is a thing of the past. Another pharma stock is positioning itself for a place in your portfolio.
Blood-Thinner Drug Race Is Still Wide Open
The major pharmaceutical companies are hoping to supply the definitive treatments, but the medical community hasn't yet declared a winner.
Merck CEO Pledges Drug Pipeline Will Yield Results in Both Short and Long Term
Merck CEO Kenneth Frazier acknowledges company's lagging stock, touts potential of numerous drugs in late development stages.
Bio-Rad Shares Make the Grade Over Alere
The medical testing sector is booming, but Bio-Rad has shown the ability to consistently generate profit.
Pfizer’s Latest Gambit for Keeping Lipitor Alive
Like a vampire refusing to die, Lipitor keeps on going. Now, PFE has a deal to sell the cholesterol-lowering drug directly to patients at generic cost.
Gilead’s Giant Gamble in Buying Pharmasset
The $11B price tag raises the stakes big-time, and critics say Gilead is overpaying to get Pharmasset's promising hepatitis C treatment.
Bank on This Pair of Biotech Bargains
When it comes to small biotechs, one successful product can send its stock soaring. This pair of companies currently have promising treatments on the horizon.
Stocks to Watch on Cancer Vaccines’ Huge Financial Potential
These companies are making progress on new therapeutic cancer vaccines -- and success for any one of them could be huge for investors.
Big Pharma’s Emerging Markets Foray Hits Roadblocks
Companies are finding plans for global expansion aren't without hiccups.
7 Health Care Merger Plays
Here's how to play the feverish pace of M&A in the hospital sector, as big health care providers compete to get much bigger.
Why Dentsply Is a Stock to Buy
The global dental products powerhouse Dentsply (XRAY) looks set to break higher.
